Slovenia -
Slovenian -
JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)
ivabradin mylan 7,5 mg filmsko obložene tablete
mylan ireland limited - ivabradin - filmsko obložena tableta - ivabradin 7,5 mg / 1 tableta - ivabradin
European Union -
Slovenian -
EMA (European Medicines Agency)
fingolimod mylan
mylan ireland limited - fingolimod hidroklorid - multiplo sklerozo, recidivno-nakazila - imunosupresivi - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older:patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 in 5. 1)orpatients s hitro razvijajočimi se hudo recidivno nakazila multiplo sklerozo, opredeljeno z 2 ali več onemogočanje zagonov v enem letu, in z 1 ali več gadolinium krepitev poškodbe na možganih, mri ali znatno povečanje t2 lezije obremenitvi, kot je v primerjavi s predhodnim zadnjih mri.
European Union -
Slovenian -
EMA (European Medicines Agency)
sugammadex mylan
mylan ireland limited - sugammadex sodium - neuromuskularna blokada - vsi drugi terapevtski izdelki - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
European Union -
Slovenian -
EMA (European Medicines Agency)
fingolimod mylan
mylan ireland limited - fingolimod hidroklorid - multiplo sklerozo, recidivno-nakazila - imunosupresivi - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 in 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.
Slovenia -
Slovenian -
JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)
ibandronska kislina mylan 150 mg filmsko obložene tablete
mylan ireland limited - ibandronska kislina - filmsko obložena tableta - ibandronska kislina 150 mg / 1 tableta - ibandronska kislina
Slovenia -
Slovenian -
JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)
mirtazapin mylan 45 mg orodisperzibilne tablete
mylan ireland limited - mirtazapin - orodisperzibilna tableta - mirtazapin 45 mg / 1 tableta - mirtazapin
Slovenia -
Slovenian -
JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)
mirtazapin mylan 30 mg orodisperzibilne tablete
mylan ireland limited - mirtazapin - orodisperzibilna tableta - mirtazapin 30 mg / 1 tableta - mirtazapin
Slovenia -
Slovenian -
JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)
gemcitabin mylan 38 mg/ml prašek za raztopino za infundiranje
mylan s.a.s. - gemcitabin - prašek za raztopino za infundiranje - gemcitabin 38 mg / 1 ml - gemcitabin
Slovenia -
Slovenian -
JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)
gemcitabin mylan 38 mg/ml prašek za raztopino za infundiranje
mylan s.a.s. - gemcitabin - prašek za raztopino za infundiranje - gemcitabin 38 mg / 1 viala - gemcitabin
Slovenia -
Slovenian -
JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)
gemcitabin mylan 40 mg/ml koncentrat za raztopino za infundiranje
mylan s.a.s. - gemcitabin - koncentrat za raztopino za infundiranje - gemcitabin 40 mg / 1 ml - gemcitabin